Summary | |
---|---|
Symbol | ILF3 |
Name | interleukin enhancer binding factor 3, 90kDa |
Aliases | NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ...... |
Chromosomal Location | 19p13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus, nucleolus Cytoplasm Nucleus Note=Localizes in the cytoplasm in response to viral infection. The unphosphorylated form is retained in the nucleus by ILF2. Phosphorylation at Thr-188 and Thr-315 causes the dissociation of ILF2 from the ILF2-ILF3 complex resulting in a cytoplasmic sequestration of ILF3. Localized in cytoplasmic mRNP granules containing untranslated mRNAs. |
Domain |
PF00035 Double-stranded RNA binding motif PF07528 DZF domain |
Function |
RNA-binding protein that plays an essential role in the biogenesis of circular RNAs (circRNAs) which are produced by back-splicing circularization of pre-mRNAs. Within the nucleus, promotes circRNAs processing by stabilizing the regulatory elements residing in the flanking introns of the circularized exons. Plays thereby a role in the back-splicing of a subset of circRNAs (PubMed:28625552). As a consequence, participates in a wide range of transcriptional and post-transcriptional processes. Upon viral infection, ILF3 accumulates in the cytoplasm and participates in the innate antiviral response (PubMed:21123651). Mechanistically, ILF3 becomes phosphorylated and activated by the double-stranded RNA-activated protein kinase/PKR which releases ILF3 from cellular mature circRNAs. In turn, unbound ILF3 molecules are able to interact with and thus inhibit viral mRNAs (PubMed:21123651, PubMed:28625552). |
Biological Process |
GO:0006417 regulation of translation GO:0009615 response to virus GO:0010608 posttranscriptional regulation of gene expression GO:0017148 negative regulation of translation GO:0019058 viral life cycle GO:0019079 viral genome replication GO:0034248 regulation of cellular amide metabolic process GO:0034249 negative regulation of cellular amide metabolic process GO:0043900 regulation of multi-organism process GO:0043901 negative regulation of multi-organism process GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism GO:0045069 regulation of viral genome replication GO:0045071 negative regulation of viral genome replication GO:0048525 negative regulation of viral process GO:0050792 regulation of viral process GO:0051607 defense response to virus GO:0098542 defense response to other organism GO:1903900 regulation of viral life cycle GO:1903901 negative regulation of viral life cycle |
Molecular Function |
GO:0003725 double-stranded RNA binding |
Cellular Component | - |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | ILF3 |
Name | interleukin enhancer binding factor 3, 90kDa |
Aliases | NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ...... |
Chromosomal Location | 19p13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between ILF3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | ILF3 |
Name | interleukin enhancer binding factor 3, 90kDa |
Aliases | NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ...... |
Chromosomal Location | 19p13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of ILF3 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | ILF3 |
Name | interleukin enhancer binding factor 3, 90kDa |
Aliases | NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ...... |
Chromosomal Location | 19p13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of ILF3 in various data sets.
|
Points in the above scatter plot represent the mutation difference of ILF3 in various data sets.
|
Summary | |
---|---|
Symbol | ILF3 |
Name | interleukin enhancer binding factor 3, 90kDa |
Aliases | NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ...... |
Chromosomal Location | 19p13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ILF3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | ILF3 |
Name | interleukin enhancer binding factor 3, 90kDa |
Aliases | NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ...... |
Chromosomal Location | 19p13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ILF3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ILF3. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | ILF3 |
Name | interleukin enhancer binding factor 3, 90kDa |
Aliases | NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ...... |
Chromosomal Location | 19p13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ILF3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | ILF3 |
Name | interleukin enhancer binding factor 3, 90kDa |
Aliases | NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ...... |
Chromosomal Location | 19p13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of ILF3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | ILF3 |
Name | interleukin enhancer binding factor 3, 90kDa |
Aliases | NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ...... |
Chromosomal Location | 19p13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between ILF3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | ILF3 |
Name | interleukin enhancer binding factor 3, 90kDa |
Aliases | NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ...... |
Chromosomal Location | 19p13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting ILF3 collected from DrugBank database. |
There is no record. |